All News

Key takeaways from the 43rd Miami Breast Cancer Conference focused on managing oligometastatic and oligoprogressive breast cancer with metastasis-directed therapy.

Gary L. Clayman, DMD, MD, FACS, discussed evaluating the link between GLP-1 receptor agonists and thyroid cancer.

According to Sebnem Ece Eksi, PhD, sympathetic signals led to shifts in cancer-associated fibroblasts to a more inflammatory state.

The future of radiation oncology will be largely impacted by artificial intelligence and genomics, according to Sheila D. Rege, MD, FACRO.

By harnessing investigator-generated data, companion diagnostics, and biomarker-directed treatment selection, clinicians can optimize care for HSPC.

Zolucatetide yielded a DCR of 100% and ORR of 80% among patients with secretase-naïve and secretase-treated desmoid tumors.

According to Brian Henick, MD, understanding why certain patients experience specific AEs will be key for giving more precise lung cancer therapy.

Bridget Koontz, MD, discussed evaluating the role of concurrent hormone therapy and brachytherapy for prostate cancer that she presented at ASCO GU.

A study published by Sebnem Ece Eksi, PhD, and coauthors, found that sympathetic nerves affect cancer-associated fibroblasts in a way that remodels the tissue environment.

DecisionDx-Melanoma’s i31-SLNB accurately predicted low nodal positivity and high recurrence-free survival in patients with cutaneous melanoma.

No patients with frontline acute myeloid leukemia experienced cytokine release syndrome following treatment with mipletamig plus venetoclax/azacitidine.

Host Brandon Mancini, MD, MBA, FACRO, discusses presentations from ASCO GU 2026 featuring potential advances in the use of radiotherapeutic regimens.

Brian Henick, MD, discussed plans to investigate agents targeting ULBP-2/5/6, antibody drug conjugates, and other novel therapies in lung cancer research.

Tousimis explored the feasibility, complications, and surgical strategies for nipple-sparing mastectomy in patients with a history of radiation therapy.

Data from the REZILIENT1 trial support the NDA for zipalertinib for patients with advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations.

Sebnem Ece Eksi, PhD, discussed how sympathetic signaling drives CAF activation and tissue remodeling to support tumor progression in pancreatic cancer.

Denileukin diftitox plus pembrolizumab achieved an ORR of 24% among patients with relapsed or refractory gynecologic cancers.

The agency highlighted regulatory compliance issues associated with a third-party facility referenced in the application for retifanlimab.

SkinCure Oncology filed a federal lawsuit against CMS and HHS to challenge the elimination of reimbursement for image-guided radiation therapy for non-melanoma skin cancer.

The VIKTORIA-1 trial findings showed that gedatolisib plus fulvestrant with or without palbociclib significantly improved PFS in PIK3CA wild-type advanced breast cancer.

Marc Lehrer Greenwald, MD, spoke with CancerNetwork® about how North Shore University Hospital treats young patients with colorectal cancer.

An independent data monitoring committee advised that the risks associated with emergent secondary hematologic malignancies may outweigh the benefits.

Education, REMS certification, and long-term management are key barriers to the widespread adoption of bispecific antibodies in the community setting.

Data from the POD1UM-303/InterAACT-2 trial support the approval of the retifanlimab regimen in first-line squamous cell carcinoma of the anal canal.

No grade 3 or greater treatment-related AEs or discontinuations were observed among patients with bladder cancer treated with the investigational agent.

The FDA granted priority review to T-DXd for patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.

Investigators will present detailed findings from the phase 3 SUCCESSOR-2 trial at a later medical meeting.

Having a “tool belt” with iberdomide and many other combinable drugs may help lead to a cure in multiple myeloma, said Sagar Lonial, MD, FACP, FASCO.

Explore 5 essential takeaways for oncology clinicians regarding the use of GLP-1 receptor agonists in breast cancer management.

Marc Lehrer Greenwald, MD, discussed a recent patient case he had with a 22-year-old woman who was diagnosed with colorectal cancer.